Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannamedical Hybrid Forte is a branded line of **medical cannabis flower** products marketed by Cannamedical Pharma for pharmacy dispensing in Germany. It consists of dried whole *Cannabis sativa* L. inflorescences from hybrid cultivars with relatively high tetrahydrocannabinol content, generally around 21% to 25%, and low cannabidiol content, typically below 1%. As a botanical natural-product drug, its pharmacology is driven primarily by phytocannabinoids, especially THC, which acts mainly as a partial agonist at cannabinoid receptors in the endocannabinoid system, with downstream effects on nociception, mood, appetite, sleep, and spasticity-related pathways. The product line includes distinct strain-specific presentations such as MAC 1, Gorilla Zkittlez, Blunicorn, Ghost Train Haze, and Critical Bilbo, sourced from multiple countries and supplied for physician-directed medical use in indications such as chronic pain and other symptom-driven conditions where medical cannabis is prescribed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cannamedical Hybrid Forte.